Nucleate UK (LinkedIn) · May 2026
Founder-story article describing Nanograb's path from Imperial College London into a startup, highlighting the early decisions behind the company.
AI-generated binders for targeted drug delivery
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Nanograb is a 2023 London-based, Y Combinator S23 biotechnology company building AI-designed multivalent nanoparticles and peptide-binder systems for cell-selective, non-viral gene delivery.
Primary product
AI-designed multivalent nanoparticles for targeted non-viral gene therapy / cell-selective drug delivery
Founded
2023
Headquarters
London, England, United Kingdom
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Computational drug discovery and nanomedicine
Offices
London, England, United Kingdom
San Francisco, California, United States
Business model
B2B biopharma partnerships
Collaborative R&D for targeted drug delivery
Funding
Stage
pre-seed
Total raised
$500K
Latest round
Pre-Seed · Sep 2023
Latest amount
$500K
Sep 2023 · Y Combinator
Jan 2023
Jan 2023
People & investors
Leadership
Co-Founder and CEO
Co-Founder and Product Lead
Co-Founder and In Silico Lead
Co-Founder and Chief Scientist
Founding Scientist (Lab)
Founding Scientist (In Silico)
Founder & Scientific Advisor
Work & culture
Science-first, translational biotech culture with strong academic roots and a partnership-oriented focus on biopharma collaboration.
Product & market
Differentiators
- —AI-generated combinations of peptide binders
- —Multivalent nanoparticle platform for cell-specific delivery
- —Designed to minimize off-target binding and side effects
- —Proof-of-concept data in vitro and in vivo
- —Aims at previously inaccessible tissues / body sites
Technology
generative AI
multivalent physics engine
peptide binder design
multivalent nanoparticles
targeted LNPs
cell-selective drug delivery
in vitro/in vivo proof-of-concept
Squarespace Commerce
reCAPTCHA
core-js
Customers
biopharma companies
drug developers
Scale & contact
Estimated revenue
US$0.4M–US$0.9M estimated annual revenue
Latest news
Nanograb (LinkedIn) · May 2026
Nanograb said CEO Debesh Mandal would present progress on multi-peptide targeted LNPs for cell-specific delivery, with work from Sara Carvalho, Daniele Visco, Shanil Panara, Christopher Lau, Debesh Mandal, and Stefano Angioletti-Uberti.
Nordic9 · Apr 2024
Funding write-up noting Nanograb's capital raise and investor set, including Y Combinator, Imperial College Innovation Fund, and Sterling Road.
HireTop · Sep 2023
Article summarizing Nanograb's targeted drug delivery approach, its AI and multivalent physics engine, and its proof-of-concept in vitro/in vivo work.
The Stevens Group · Jan 2023
Official launch announcement describing Nanograb as a computational drug discovery company using AI to generate binders for precise drug delivery.
Jobs and careers at Nanograb
0 jobs at Nanograb
No open positions
Check back later for new openings